A PHASE III, OPEN-LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA

Registry ID

GO30182

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2016-10-20

Last update

2016-06-29

Conditions

• COLORECTAL ADENOCARCINOMA

Related clinical trials

• A PHASE III STUDY OF BOTENSILIMAB + BALSTILIMAB VERSUS BEST SUPPORTIVE CARE IN CHEMO-REFRACTORY UNRESECTABLE COLORECTAL ADENOCARCINOMA: THE BATTMAN TRIAL
• A PHASE II STUDY OF PERIOPERATIVE QBECO SITE SPECIFIC IMMUNOMODULATOR (QU BIOLOGICS®) IN PATIENTS WITH METASTATIC COLORECTAL ADENOCARCINOMA WITHIN THE LIVER UNDERGOING RESECTION

View on source registry